189 related articles for article (PubMed ID: 5777697)
21. Evaluation of an injectable progestin-estrogen as a contraceptive.
Scommegna A; Lee AW; Borushek S
Am J Obstet Gynecol; 1970 Aug; 107(8):1147-55. PubMed ID: 4917852
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study of different doses of Depo Provera.
Fotherby K; Koetsawang S; Mathrubutham M
Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
[TBL] [Abstract][Full Text] [Related]
23. [Femigen forte and mite preparations in contraception and gynecologival disorders].
Sternadel Z; Pietrusiewicz W; Wasilewska B
Ginekol Pol; 1970 Nov; 41(11):1227-36. PubMed ID: 4098877
[TBL] [Abstract][Full Text] [Related]
24. [Contraception with injectable long-acting preparation depo-provera].
Prilepskaia VN; Kondrikov NI; Tagieva TT
Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
[TBL] [Abstract][Full Text] [Related]
25. Lynestrenol 1 mg.-mestranol 0.1 mg: a new low dose oral contraceptive: a clinical study.
Kamal I; Hefnawi F; Younis N
Egypt Popul Fam Plann Rev; 1970 Jun; 3(1):11-5. PubMed ID: 12254506
[TBL] [Abstract][Full Text] [Related]
26. Serium protein-bound carbohydrate and seromucoid levels during long-acting progestational contraceptive therapy.
Saleh FM
Contraception; 1977 Oct; 16(4):399-407. PubMed ID: 923250
[TBL] [Abstract][Full Text] [Related]
27. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use.
Belsey EM
Contraception; 1988 Aug; 38(2):207-25. PubMed ID: 2971506
[TBL] [Abstract][Full Text] [Related]
28. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
29. The effect of an oral contraceptive on tests of thyroid function.
Mishell DR; Colodny SZ; Swanson LA
Fertil Steril; 1969; 20(2):335-9. PubMed ID: 4179961
[TBL] [Abstract][Full Text] [Related]
30. Effect of nor-ethisterone enanthate (SH 393) on the structure of the endometrium and on the cervical mucus.
Achari K
J Obstet Gynaecol India; 1969; 19(6):731-6. PubMed ID: 12255497
[TBL] [Abstract][Full Text] [Related]
31. Use of Anovlar in gynaecological disorders and contraception.
Shahani SM; Chiklikar A
J Obstet Gynaecol India; 1968 Apr; 18(2):592-7. PubMed ID: 12331827
[TBL] [Abstract][Full Text] [Related]
32. Depo Provera: still controversial.
Wren LM
Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
[TBL] [Abstract][Full Text] [Related]
33. Endometrial changes induced by the administration of an oral contraceptive, norethindrone (S-3800B).
Utsumi K; Kuribayashi N; Kumakiri S
Acta Pathol Jpn; 1966 May; 16(2):141-50. PubMed ID: 6012525
[TBL] [Abstract][Full Text] [Related]
34. Problems in evaluating chronic toxicity of contraceptive steroids in dogs.
Weikel JH; Nelson LW
J Toxicol Environ Health; 1977 Sep; 3(1-2):167-77. PubMed ID: 72828
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
36. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
37. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
38. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
Pardthaisong T; Gray RH; McDaniel EB
Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
[TBL] [Abstract][Full Text] [Related]
39. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
Laatikainen T; Nieminen U; Adlercreutz H
Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
[TBL] [Abstract][Full Text] [Related]
40. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
